Drugs moving into the clinic: 18
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| BiolineRx | BL-1040 | Cardiovascular | Absorbable liquid polymer that forms a protective scaffold to enhance the mechanical strength of the heart muscle post acute myocardial infarction, in order improve cardiac function and survival |
| Alkermes | AIR parathyroid hormone (AIR PTH) | osteoporosis | Inhaled formulation of Eli Lilly's recombinant parathyroid hormone, Forteo (teriparatide (rDNA origin) injection) |
| KaloBios Pharma- ceuticals | KB001 | Anti-infectives and Vaccines - Pseudomonas aeruginosa infections | Antibody that neutralizes the PcrV protein of the Type III secretion system of the P. aeruginosa bacterium, which directly inhibits its toxic effects |
| Viventia Biotech | VB6-845 | Oncology - epithelial tumours | Antibody fragment targeting EpCAM fused with deimmunized form of the cytotoxic (ribosome inactivating) protein Bouganin |
| Erimos Pharmac- euticals | EM-1421- terameprocol | Oncology - solid tumours | Synthetic tetra-methylated derivative of nordihydro- guaiaretic acid (NDGA) to prevent production and activation of survivin, thus preventing cell replication and enhancing the body's ability to eliminate abnormal cells through cell death |
| Quest PharmaTech | SL017 Topical Gel | Pre-oncology - actinic keratosis (AK) | Photodynamic therapy based on Hypocrellin B (HB), which sensitises the tissue for destruction |
